Literature DB >> 15846459

Data supplementation: a pharmacokinetic/pharmacodynamic knowledge creation approach for characterizing an unexplored region of the response surface.

Ene I Ette1, Hui-May Chu, Christopher J Godfrey.   

Abstract

PURPOSE: To develop a data supplementation [i.e., a pharmacokinetic/pharmacodynamics (PK/PD) knowledge creation] approach for generating supplemental data to be used in characterizing a targeted unexplored segment of the response surface.
METHODS: The procedure for data supplementation can be summarized as follows: 1) statement of the objective of data supplementation for PK/PD knowledge creation, 2) performance of PK knowledge discovery, 3) PK data synthesis for target dose group(s), 4) covariate data synthesis for virtual subjects in the target dose group(s), 5) discovery of hidden knowledge from real data set to which supplemental data will be added, 6) implementation of a data supplementation methodology, and 7) discovery and communication of the created knowledge. A nonparametric approximate Bayesian multiple supplementation and its modification, structure-based multiple supplementation, which is an adaptation of the approximate Bayesian bootstrap, is proposed as a method of data supplementation for PK/PD knowledge creation. The structured-based multiple supplementation methodology was applied to characterize the effect of a target dose of 100 mg that was unexplored in a previously concluded study that investigated the effect of 200- and 600-mg doses on biomarker response.
RESULTS: The target dose of 100 mg was found to produce a response comparable with that of the 200 mg and better than that obtained with the 600 mg.
CONCLUSIONS: Implementation of the PK/PD knowledge creation process through data supplementation resulted in gaining knowledge about a targeted region of a response surface (i.e., the effect of a target dose) that was not previously studied in a completed study without expending resources in conducting a new study.

Entities:  

Mesh:

Year:  2005        PMID: 15846459     DOI: 10.1007/s11095-005-2499-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  The process of knowledge discovery from large pharmacokinetic data sets.

Authors:  E I Ette; P Williams; E Fadiran; F O Ajayi; L C Onyiah
Journal:  J Clin Pharmacol       Date:  2001-01       Impact factor: 3.126

2.  Risks in new drug development: approval success rates for investigational drugs.

Authors:  J A Dimasi
Journal:  Clin Pharmacol Ther       Date:  2001-05       Impact factor: 6.875

3.  Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.

Authors:  Ene I Ette; Leonard C Onyiah
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.441

Review 4.  Expanding clinical applications of population pharmacodynamic modelling.

Authors:  C Minto; T Schnider
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

5.  Stability and performance of a population pharmacokinetic model.

Authors:  E I Ette
Journal:  J Clin Pharmacol       Date:  1997-06       Impact factor: 3.126

Review 6.  Learning versus confirming in clinical drug development.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1997-03       Impact factor: 6.875

Review 7.  New approaches and technologies in drug design and discovery.

Authors:  M L Kleinberg; L A Wanke
Journal:  Am J Health Syst Pharm       Date:  1995-06-15       Impact factor: 2.637

8.  Computer simulation as a tool for clinical trial design.

Authors:  D R Jones
Journal:  Int J Biomed Comput       Date:  1979-03

9.  Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease.

Authors:  K L Lee; J F McNeer; C F Starmer; P J Harris; R A Rosati
Journal:  Circulation       Date:  1980-03       Impact factor: 29.690

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.